The myeloid differentiation protein MyD88 (myeloid differentiation primary response protein) was originally identified and characterized as a primary upregulated response gene in interleukin-6 mediated myeloid differentiation. Now, MyD88 is known to be an essential cytosolic adaptor protein in the innate and adaptive immune responses controlled by the interleukin-1 signaling pathway, and MyD88 antibodies have shown that it is expressed in many tissues (1).
Studies with MyD88 antibodies have shown that MyD88 directly associates with and recruits the IL-1 receptor-associated kinase protein (IRAK) in response to IL-1, leading to IRAK phosphorylation, and eventual downstream activation of NFkB (2). In addition to its key role in IL-1 signaling, MyD88 also regulates the Toll/IL-1R family of receptors involved in the inflammatory responses of IL-1, IL-18, and LPS (lipopolysaccharides) as demonstrated through use of MyD88 antibodies (3). There is great interest in targeting the TLRs (Toll-like receptors) as therapeutics for cancer, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease (4). Current investigations are underway to test the validity of using MyD88 antibodies embedded in microarrays as clinical prognostic factors for ovarian and colorectal cancers (5,6) as well as for predictive biomarkers of neoadjuvant chemotherapy resistance in breast cancer (7).
Novus Biologicals offers MyD88 reagents for your research needs including:
